RxDoctor Payments Data

Aneesh Tolat, MD

Clinical Cardiac Electrophysiology · Hartford, CTNPI 1053356519

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $34,083 of the $52,921 with a category attached, or 64.4%. 11 manufacturers reported payments, led by Abbott at 49.2% of the total.

$52,921in general payments, 2019–2025

Across 168 payments — averaging $315.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$26K
  • Medtronic$20K
  • Siemens Medical Solutions USA, Inc.$3K
  • Atricure, Inc.$2K
  • Biosense Webster, Inc.$968
  • Boston Scientific$507
  • plus $387 from 5 others
$683,850in research payments, 2019–2025

Across 32 payments — averaging $21,370 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Siemens Medical Solutions USA, Inc.$542K
  • Biosense Webster, Inc.$90K
  • Medtronic$30K
  • Abbott$21K

What the payments were for

  • Consulting fees$34,08364%
  • Speaking & faculty fees$5,92511%
  • Travel & lodging$6,61713%
  • Food & beverage$6,29712%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,921 in reported general payments places this provider in the 75th percentile of 47 clinical cardiac electrophysiology providers in Connecticut.

See all clinical cardiac electrophysiology providers in Connecticut

Medicare billing

Part B allowed, 2024
$102,930
Medicare patients
443
Services billed
1,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$12,683
XareltoRivaroxaban11$7,687
Dofetilide14$5,059
Flecainide Acetate39$2,385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$12,68312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 47 clinical cardiac electrophysiology providers in Connecticut.

Other clinical cardiac electrophysiology in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →